Related Experiment Video
Updated: Sep 27, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.3K
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches
Nathan M Hawkey1, Alton O Sartor2, Michael J Morris3
1Department of Medicine, Duke University School of Medicine, Division of Medical Oncology, Durham, North Carolina.
Clinical Advances in Hematology & Oncology : H&O
|April 7, 2022
Summary
Prostate-specific membrane antigen (PSMA)-targeted theranostics offer new hope for metastatic castration-resistant prostate cancer (mCRPC) patients. This approach uses PSMA
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Prostate cancer, despite high survival rates, remains a leading cause of cancer death, primarily due to metastatic disease.
- Metastatic castration-resistant prostate cancer (mCRPC) patients have limited treatment options and a poor prognosis.
- Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, making it a specific target.
Purpose of the Study:
- To review the development of PSMA-directed theranostics for prostate cancer.
- To discuss the clinical implications, limitations, and future directions of PSMA-targeted therapies.
Main Methods:
- Review of current literature on PSMA-directed theranostics.
- Discussion of approved and investigational PSMA-targeted agents.
- Analysis of clinical trial data and FDA reviews.
Main Results:
- PSMA-directed radiodiagnostics (PET/CT) are FDA-approved.
- Lutetium Lu 177 PSMA-617 therapy is under priority FDA review.
- Novel PSMA-targeted therapies, including ligand-drug and cellular immunotherapies, are under clinical investigation.
Conclusions:
- PSMA-directed theranostics show significant promise for treating prostate cancer.
- Further research and clinical trials are needed to optimize these therapies.
- PSMA theranostics represent a rapidly evolving field with potential to improve outcomes for mCRPC patients.
